SCHEMBL6589502

SCHEMBL6589502

C#CCn1cc(CCN2CCN(c3cccc4c3OCCO4)CC2)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.60
HTR1A P08908 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL6784806 0.95 DRD2 (0.54) DRD2HTR1A
SCHEMBL6592915 0.86 DRD2 (0.60) DRD2HTR1A
SCHEMBL6590561 0.86 DRD2 (0.59) DRD2HTR1A
Oxalic Acid SCHEMBL6771629 0.82 DRD2 (0.54) DRD2HTR1A
Oxalic Acid SCHEMBL6588728 0.81 DRD2 (0.54) DRD2HTR1A
SCHEMBL6588661 0.80 DRD2 (0.59) DRD2HTR1A
SCHEMBL8304293 0.78 DRD2 (0.70) DRD2HTR1A
Oxalic Acid SCHEMBL6592488 0.78 DRD2 (0.56) DRD2HTR1A
SCHEMBL6611400 0.76 DRD2 (0.66) DRD2HTR1A
SCHEMBL6589414 0.75 DRD2 (1.00) DRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1007523-B9 INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE LUNDBECK & CO AS H (DK) 2004-09-08 EP claimed
CN-1127501-C indole and 2, 3-indoline derivatives, their preparation and use LUNDBECK & CO AS H (DK) 2003-11-12 CN claimed
EP-1007523-B1 INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE LUNDBECK & CO AS H (DK) 2003-10-22 EP claimed
US-6476035-B1 Indole and 2,3-dihydroindole derivatives, their preparation and use H. LUNDBECK A/S (DK) 2002-11-05 US claimed
EP-1007523-B9 INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE LUNDBECK & CO AS H (DK) 2004-09-08 EP disclosed
CN-1515568-A Indole and 2,3-indoline derivative, their preparation and application H.隆德贝克有限公司 2004-07-28 CN disclosed
CN-1515569-A Indole and 2,3-indoline derivative, their preparation and application H.隆德贝克有限公司 2004-07-28 CN disclosed
US-6727263-B2 SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION H. LUNDBECK A/S (DK) 2004-04-27 US disclosed
EP-1007523-B1 INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE LUNDBECK & CO AS H (DK) 2003-10-22 EP disclosed
US-20030018050-A1 Indole and 2,3-dihydroindole derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018050-A1 Indole and 2,3-dihydroindole derivatives, their preparation and use TPH1, HTR1A, HTR3A DRD2 26/4885HTR1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.